Evidence map›Paper›PMID 38690893›Full record

ArticleAntimicrobial agents and chemotherapy2024

Bactericidal and sterilizing activity of sudapyridine-clofazimine-TB47 combined with linezolid or pyrazinamide in a murine model of tuberculosis.

Wei Yu, Yanan Ju, Xingli Han, Xirong Tian, Jie Ding, Shuai Wang, H M Adnan Hameed, Yamin Gao, Lei Li, Yongguo Li and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Assessment of TB47 as a potential novel therapeutic agent:Antimicrobial agents and chemotherapy · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Wei Yu *State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.ORCID 0000-0001-5287-818X
Yanan Ju *State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Xingli HanState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Xirong TianState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Jie DingState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Shuai WangState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
H M Adnan HameedState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Yamin GaoState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Lei LiShanghai Jiatan Pharmatech Co., Ltd, a subsidiary of Guangzhou JOYO Pharma Ltd., Shanghai, China.
Yongguo LiShanghai Jiatan Pharmatech Co., Ltd, a subsidiary of Guangzhou JOYO Pharma Ltd., Shanghai, China.
Nanshan ZhongGuangzhou National Laboratory, Guangzhou, China.
Tianyu ZhangState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.ORCID 0000-0001-5647-6014
Chinese Academy of Sciences · CNUniversity of Science and Technology of China · CNAnhui University · CNFirst Affiliated Hospital of Guangzhou Medical University · CN

Funding

CAS President International Fellowship Initivate 2023VBC0015China Postdoctoral Science Foundation (China Postdoctoral Foundation Project) 2022M723164GDSTC | Basic and Applied Basic Research Foundation of Guangdong Province 2022A1515110883, 2022A1515110505Guangdong Science and Technology Plan-Youth Doctral Sail Project 2024A04J4273MOST | National Key Research and Development Program of China (NKPs) 2021YFA1300900MOST | National Natural Science Foundation of China (NSFC) 82304575, 32300152, 21920102003National Foreign Expert Project - Foreign Young Talents Program QN2022031002LState Key Lab of Respiratory Disease, Guangzhou Institute of Respiratory Diseases, First Affiliated Hospital of Guangzhou Medical University SKLRD-Z-202301, SKLRD-OP-202324, SKLRD-Z-202414, SKLRD-Z-202412
6 · The paper itself

Abstract

As an obligate aerobe,

Indexed as

Antitubercular AgentsClofazimineDiarylquinolinesDisease Models, AnimalLinezolidMycobacterium tuberculosisPyrazinamideAnimalsDrug SynergismDrug Therapy, CombinationFemaleMiceMice, Inbred BALB CMicrobial Sensitivity TestsSpiro CompoundsThiazines2-(2-methyl-1,4-dioxa-8-azaspiro(4.5)dec-8-yl)-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-oneAntitubercular AgentsbedaquilineClofazimineDiarylquinolinesLinezolidPyrazinamideSpiro CompoundsThiazinesdrug resistanceelectron transport chainsudapyridineTB47tuberculosis

Identifiers

PMID38690893
PMCPMC11620513
OpenAlexW4396553456

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.